statements

Novelix Pharmaceuticals Ltd.

BSE: 536565

Sector: Consumer Services

Industry Group: Retailing

Industry: Pharmacy Retail

70.64-1.4 (-1.89%)

8 Jul, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Novelix Pharmaceuticals Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	C 2013 Mar 31	R 2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	12.27	5.96	5.77	6.35	5.72	9.19	10.50	10.46	10.24	9.24	0.84	1.40	4.22	30.72	132.31
Cost of Operating Revenue	-	4.83	4.53	5.00	4.46	7.95	8.99	9.26	9.36	8.77	0.88	1.41	3.87	29.61	126.82
Gross Profit	12.27	1.13	1.24	1.35	1.25	1.23	1.51	1.20	0.89	0.47	-0.04	0.00	0.35	1.11	5.49
Gross Margin	100.0	18.9	21.6	21.2	21.9	13.4	14.4	11.5	8.6	5.1	-4.3	-0.3	8.3	3.6	4.1
Total Operating Expenses	11.67	5.40	5.14	5.87	5.61	9.11	10.75	10.83	10.95	13.25	1.19	1.98	4.51	30.61	128.93
Operating Profit	0.60	0.56	0.63	0.48	0.11	0.08	-0.24	-0.37	-0.70	-4.01	-0.34	-0.57	-0.29	0.11	3.37
Operating Margin	4.9	9.4	10.9	7.6	1.9	0.8	-2.3	-3.6	-6.8	-43.4	-40.9	-40.9	-6.8	0.4	2.5
Financing Income/(Expense) - Net	0.01	-0.01	-0.01	0.00	0.00	-0.05	-0.16	-0.13	-0.11	-0.05	-1.50	0.24	0.06	0.00	-
Profit before Taxes	0.61	0.55	0.64	0.27	0.24	0.19	-0.21	-0.12	-0.21	-3.75	-1.57	-0.06	0.02	0.12	3.40
Income Taxes	0.14	0.17	0.20	0.13	0.11	0.16	0.14	0.02	0.04	0.01	-0.01	0.00	0.01	0.04	0.85
Profit after Tax	0.46	0.38	0.43	0.09	0.10	-0.01	-0.39	-0.24	-0.28	-3.74	-1.56	-0.06	0.01	0.08	2.56
PAT Margin	3.8	6.3	7.4	1.3	1.7	-0.1	-3.7	-2.3	-2.8	-40.5	-185.1	-4.3	0.2	0.3	1.9
EPS - Basic - ex Extraordinary Items	0.69	0.47	0.53	0.11	0.12	-0.01	-0.48	-0.30	-0.35	-4.62	-1.93	-0.07	0.01	0.09	1.21
EPS - Diluted - ex Extraordinary Items	0.69	0.47	0.53	0.11	0.12	-0.01	-0.48	-0.30	-0.35	-4.62	-1.93	-0.07	0.01	0.09	1.21
EBIT	0.60	0.56	0.63	0.48	0.11	0.08	-0.24	-0.37	-0.70	-4.01	-0.34	-0.57	-0.29	0.11	3.37
EBITDA	0.86	0.82	0.91	0.89	0.46	0.27	-0.01	-0.16	-0.51	-3.80	-0.27	-0.52	-0.25	0.15	3.47
EBITDA Margin	7.0	13.8	15.8	14.0	8.1	2.9	-0.1	-1.5	-5.0	-41.1	-32.4	-36.9	-5.9	0.5	2.6

Balance Sheet

Abridged

Understanding Balance Sheet

Novelix Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	11.12	9.96	10.78	10.32	11.44	10.91	10.56	10.72	11.39	7.33	4.63	4.24	4.13	26.93	88.91
Long-Term Investments	0.51	0.02	0.05	1.14	0.05	0.33	0.63	0.49	0.30	0.39	2.33	2.78	3.06	0.04	0.04
Property Plant & Equipment - Net	0.55	0.62	0.74	0.53	0.93	2.06	2.15	1.89	1.78	1.62	0.23	0.17	0.12	0.19	1.52
Total Non-Current Assets	2.20	2.18	1.43	2.19	1.30	2.71	3.02	2.62	2.33	2.24	2.62	3.01	3.24	0.27	3.51
Total Assets	13.31	11.54	12.21	12.52	12.74	13.61	13.58	13.34	13.72	9.57	7.25	7.26	7.36	27.21	92.42
Total Current Liabilities	5.06	0.33	0.39	0.73	0.65	0.69	0.95	0.99	1.81	2.17	0.01	0.06	0.01	9.67	41.61
Long Term Debt	-	0.04	0.01	-	-	0.96	0.98	0.93	0.77	-	-	-	-	-	4.32
Total Non-Current Liabilities	0.16	0.18	0.13	0.08	0.02	1.03	1.06	0.93	0.79	0.03	-	-	-	-	4.32
Total Liabilities	5.22	0.51	0.52	0.81	0.68	1.72	2.01	1.92	2.59	2.21	0.01	0.06	0.01	9.67	45.93
Total Shareholders' Equity	8.09	11.03	11.47	11.43	11.55	11.53	11.17	10.92	10.60	6.86	7.24	7.20	7.35	17.54	46.49
Minority Interest	-	-	0.22	0.28	0.51	0.36	0.41	0.50	0.52	0.50	-	-	-	-	-
Total Equity	8.09	11.03	11.69	11.70	12.06	11.89	11.57	11.42	11.13	7.37	7.24	7.20	7.35	17.54	46.49
Total Liabilities & Equity	13.31	11.54	12.21	12.52	12.74	13.61	13.58	13.34	13.72	9.57	7.25	7.26	7.36	27.21	92.42

Cash Flow

Abridged

Understanding Cash Flow Statement

Novelix Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	0.68	0.62	0.70	0.72	0.38	0.10	-0.17	-0.14	-0.17	-3.55	0.03	0.00	0.06	0.16	3.51
Working Capital - Increase/(Decrease)	-0.37	-3.35	0.20	-0.42	1.67	-1.92	0.56	-0.27	1.15	5.42	1.12	0.61	-0.10	-13.83	-25.86
Net CF from Operating Activities	0.31	-2.74	0.90	0.30	2.05	-1.81	0.39	-0.41	0.97	1.86	1.14	0.61	-0.04	-13.67	-22.36
Capital Expenditures - Net	0.00	0.14	0.24	0.10	0.55	1.29	0.35	-0.15	0.11	0.03	1.83	0.00	-0.02	0.11	3.26
Net CF from Investing Activities	-0.01	0.35	-0.13	-1.40	-1.06	0.21	-0.65	0.31	0.11	-0.14	-0.28	-0.44	-0.12	2.91	-1.76
Dividends Paid - Cash - Total	0.20	0.20	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock - Issuance/(Retirement) - Net	-	2.56	-	-	-	-	-	-	-	-	-	-	-	11.32	26.39
Debt - LT & ST - Issuance/(Retirement) - Total	-0.08	0.04	-0.03	-0.01	-	0.96	0.02	-0.05	-0.16	-0.77	-	-	-	-	-
Net Cash Flow from Financing Activities	-0.28	2.41	0.19	-0.01	0.22	0.77	0.02	-0.05	-0.16	-0.77	-	-	-	11.32	26.39
Free Cash Flow to Equity	0.23	-2.83	0.63	0.18	1.51	-2.15	0.06	-0.31	0.71	1.07	-0.69	0.61	-0.02	-13.77	-25.61
Free Operating CF net dividend	0.11	-3.10	0.66	0.20	1.51	-3.10	0.02	-0.55	0.87	1.83	-0.72	0.61	-0.04	-13.77	-25.61
Free Operating CF	0.31	-2.90	0.66	0.20	1.51	-3.10	0.02	-0.55	0.87	1.83	-0.72	0.61	-0.04	-13.77	-25.61

Business Segment Analysis

FY End:

Mar 14

Novelix Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Pharma Business (84.5%)₹ 4.86 CrFinancial Activity (15.5%)₹ 0.89 CrInvestment Activity (0.0%)₹ 0.00 Cr

Regional Segment Analysis

Novelix Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Novelix Pharmaceuticals Ltd.

Historical Segment Analysis

Track how Novelix Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Sales

Operating Income

Business

Regional

Business

We don't have enough data to show the Capex for Novelix Pharmaceuticals Ltd..

Frequently Asked Questions

What is the revenue of Novelix Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Novelix Pharmaceuticals Ltd. is ₹ 132.31 Cr, reflecting a 1-year growth of 330.70% and a 3-year CAGR of 355.00%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Novelix Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Novelix Pharmaceuticals Ltd. is ₹ 2.56 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Novelix Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Novelix Pharmaceuticals Ltd. is approximately ₹ 3.37 Cr (based on an operating margin of 2.55%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Novelix Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Novelix Pharmaceuticals Ltd. is 1.21. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Novelix Pharmaceuticals Ltd.?

The debt-to-equity ratio of Novelix Pharmaceuticals Ltd. stands at 0.09. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Novelix Pharmaceuticals Ltd.?

The estimated book value per share of Novelix Pharmaceuticals Ltd. is 19.46 (derived from a P/B ratio of 3.63 and market price of ₹ 70.64), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Novelix Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Novelix Pharmaceuticals Ltd. is ₹ -22.36 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Novelix Pharmaceuticals Ltd. report consolidated or standalone financials?

Novelix Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.